XIFAXAN® (rifaximin)

LENGTH OF AUTHORIZATION: Varies per indication

Review Criteria:
- Diarrhea caused by E. Coli – length of approval: 3 days
  - Patient must be ≥ 12 years of age.
  - Patient must not be experiencing fevers and/or bloody stools.
  - Patient must have a documented culture indicating causative microorganism is E. Coli.

- Hepatic Encephalopathy- length of approval up to 6 months
  - Patient must be ≥ 18 years of age.
  - Patient must have a confirmed (from medical records or diagnosis codes) diagnosis of hepatic encephalopathy.
  - Patient must be currently taking or have had a documented trial of lactulose.

- Irritable Bowel Syndrome (refractory)-length of approval up to 6 weeks.
  - Patient must be ≥ 18 years of age.
  - Patient must have a diagnosis of Irritable Bowel Syndrome (IBS) with diarrhea as the predominant symptom, confirmed with colonoscopic examination within the previous 2 years. (A copy of the colonoscopy results should be submitted or addressed in the MD progress notes).
  - Patient must have had a documented trial of 3 of the treatment options listed below since the diagnosis of IBS:
    1. Lifestyle and dietary modifications
       - Elimination of caffeine, lactose or fructose from diet and/or
       - Addition of fiber to diet and/or
       - Use of Probiotics
    2. Antidiarrheals (i.e. loperamide, cholestyramine)
    3. Antispasmodics (i.e. dicyclomine, hyoscyamine)
    4. Tricyclic antidepressants (i.e. desipramine, amitriptyline, doxepin)

Dosing:
- Recommended dose for the treatment of traveler’s diarrhea: 200 mg three times daily for 3 days.
- Recommended dose for the treatment of hepatic encephalopathy: 550 mg twice daily.
- Recommended dose for the treatment of IBS: 550 mg three times daily for 14 days. Dose may be repeated up to two additional times (maximum of three total treatment cycles).